Peterson Allison R, Binder Devin K
Center for Glial-Neuronal Interactions, Division of Biomedical Sciences, School of Medicine, University of California, Riverside, Riverside, CA, United States.
Front Mol Neurosci. 2019 Jul 9;12:164. doi: 10.3389/fnmol.2019.00164. eCollection 2019.
Glutamate transporter-1 (GLT-1) is a Na-dependent transporter that plays a key role in glutamate homeostasis by removing excess glutamate in the central nervous system (CNS). GLT-1 dysregulation occurs in various neurological diseases including Huntington's disease (HD), Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and epilepsy. Downregulation or dysfunction of GLT-1 has been a common finding across these diseases but how this occurs is still under investigation. This review aims to highlight post-translational regulation of GLT-1 which leads to its downregulation including sumoylation, palmitoylation, nitrosylation, ubiquitination, and subcellular localization. Various therapeutic interventions to restore GLT-1, their proposed mechanism of action and functional effects will be examined as potential treatments to attenuate the neurological symptoms associated with loss or downregulation of GLT-1.
谷氨酸转运体-1(GLT-1)是一种依赖钠离子的转运体,通过清除中枢神经系统(CNS)中过量的谷氨酸,在谷氨酸稳态中起关键作用。GLT-1失调发生在多种神经疾病中,包括亨廷顿舞蹈病(HD)、阿尔茨海默病(AD)、帕金森病(PD)、肌萎缩侧索硬化症(ALS)和癫痫。GLT-1的下调或功能障碍在这些疾病中是一个常见的发现,但具体机制仍在研究中。本综述旨在强调导致GLT-1下调的翻译后调控,包括SUMO化、棕榈酰化、亚硝基化、泛素化和亚细胞定位。将研究各种恢复GLT-1的治疗干预措施、其 proposed 作用机制和功能效果,作为减轻与GLT-1缺失或下调相关神经症状的潜在治疗方法。 (注:原文中“proposed”拼写有误,可能是“proposed”,已按正确理解翻译)